Download
fdli introduction to medical device law and regulation n.
Skip this Video
Loading SlideShow in 5 Seconds..
FDLI Introduction to Medical Device Law and Regulation PowerPoint Presentation
Download Presentation
FDLI Introduction to Medical Device Law and Regulation

FDLI Introduction to Medical Device Law and Regulation

216 Views Download Presentation
Download Presentation

FDLI Introduction to Medical Device Law and Regulation

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. FDLI Introduction to Medical Device Law and Regulation Other Postmarket Controls Philip Katz(202) 624-2660pkatz@crowell.com October 29, 2002Washington, D.C.

  2. Device Tracking • FDCA § 519(e) • 21 CFR Part 821 (amended effective May 9, 2002) • “Guidance on Medical Device Tracking” (Jan. 2000)

  3. FDCA § 519(e) • Class II or III device • Failure likely to have serious adverse health consequences • Intended to be implanted for more than one year • Life sustaining/supporting device used outside device user facility

  4. Additional Factors • Likelihood of sudden, catastrophic failure • Likelihood of significant adverse clinical outcome • Need for prompt professional intervention

  5. Device Tracking • To ensure that device can be traced from manufacturing facility to patient • Must be able to locate device quickly • Three days for undistributed device • Ten days for device distributed to patient

  6. Device Tracking • Separate order issued with PMA approval or 510(k) clearance • Methods may vary, but must have written SOPs • Can use outside contractor

  7. Device Tracking • Must audit system, to verify that it works and the information is accurate • Must maintain records as long as device is in distribution or use

  8. Device Tracking • Distributors (such as hospitals and other user facilities) must track and provide information to the manufacturer • Obligations start/stop at water’s edge • Patient can refuse identifying information

  9. Postmarket Surveillance • FDCA § 522 • 21 CFR Part 822 (effective July 8, 2002) • “Guidance on Criteria and Approaches for Postmarket Surveillance” (Nov. 1998)

  10. FDCA § 522 • Class II or III device • Failure likely to have serious adverse health consequences • Intended to be implanted for more than one year • Life sustaining/supporting device used outside device user facility

  11. Other Criteria • Important unanswered surveillance question • Availability of other postmarket mechanisms • Practicality of surveillance strategies • Magnitude of risk

  12. Postmarket Surveillance • Limitations of premarket data • Shortcomings of MDRs

  13. Postmarket Surveillance • Required by FDA order, not necessarily at time of review/clearance • Manufacturer must submit plan in 30 days • FDA has 60 days to judge plan’s adequacy

  14. Range of Methods • Literature review • Secondary data sets, registries • Studies (clinical, non-clinical)

  15. Postmarket Surveillance • Can last up to three years • Applies to foreign manufacturers • Does not apply to devices for export only • Informed consent and IRB requirements apply

  16. Postmarket Surveillance • Interim and final reports • Retain records for two years • Produce records within three days • Records subject to inspection/review

  17. Device Promotion • Advertising • Not defined, but see drug regulations • Labeling • Label and “all other written, printed or graphic matter . . . accompanying” the device

  18. Device Promotion • Misleading • FDCA § 201(n) • Not just representations made or suggested, but also material omissions

  19. FDCA § 502 – Misbranding • All devices • False or misleading labeling (FDCA § 502(a)) • Adequate directions for use, adequate warnings (FDCA § 502(f)) • Registration, listing, 510(f) notice/information (FDCA § 502(o))

  20. FDCA § 502 – Misbranding • Restricted devices • False or misleading advertising (FDCA § 502(q)) • Advertising or “other descriptive matter” lacks side effects, contraindications (FDCA § 502(r))

  21. Device Promotion • Unapproved uses • False or misleading statements

  22. Unapproved Uses • Promotion of device that is not approved or cleared • Promotion of cleared/approved device for use that is not cleared or approved • Not limited to advertising/labeling

  23. False or Misleading Statements • Shared jurisdiction • FDA – all labeling, restricted device ads • FTC – all other device ads • Sort of

  24. False or Misleading Statements • Jurisdiction makes a difference • Different outlooks • Different processes • Different results

  25. False or Misleading Statements • FDA • No clear standard • Can look to drug ad regulations • Can look to FTC

  26. False or Misleading Statements • FTC • Identifying the representation • Determine whether it’s true and substantiated

  27. FTC • Identify the representation • Express and implied claims • Intent irrelevant • Reasonable interpretation by target audience

  28. FTC • Is the claim true and substantiated? • Implied presence of substantiation • “Establishment” claims • True + false = false

  29. Other Issues • Internet • First Amendment

  30. FDLI Introduction to Medical Device Law and Regulation Other Postmarket Controls Philip Katz(202) 624-2660pkatz@crowell.com October 29, 2002Washington, D.C.